论文部分内容阅读
目的探讨纤溶酶治疗脑卒中患者残疾功能疗效。方法选取2016年1月—2017年2月78例脑卒中患者作为研究对象,根据随机数字表分为观察组和对照组,每组39例。其中,对照组给予常规的康复治疗,观察组在对照组的治疗基础上给予纤溶酶治疗,两组均治疗2周。比较两组脑卒中治疗总有效率、不良反应发生率及治疗前后患者神经功能缺损评分、血小板聚集度、红细胞聚集指数、溶酶体颗粒膜糖蛋白。结果观察组脑卒中治疗总有效率94.87%高于对照组的76.92%(P<0.05);观察组不良反应发生率与对照组相同,差异无统计学意义(P>0.05)。两组治疗前神经功能缺损评分、血小板聚集度、红细胞聚集指数、溶酶体颗粒膜糖蛋白比较差异无统计学意义(P>0.05);治疗后观察组神经功能缺损评分、血小板聚集度、红细胞聚集指数、溶酶体颗粒膜糖蛋白均低于对照组(P<0.05)。结论纤溶酶改善脑卒中患者残疾功能疗效确切,可有效改善患者血液流变学指标,减轻神经功能缺损症状,促进患者预后的改善,且药物治疗后未出现严重不良反应,具有较好的安全性。
Objective To investigate the effect of plasmin on disability in patients with stroke. Methods From January 2016 to February 2017, 78 stroke patients were selected as study subjects. According to random number table, the patients were divided into observation group and control group, 39 cases in each group. Among them, the control group was given routine rehabilitation treatment, the observation group was treated with plasmin on the basis of the control group, and both groups were treated for 2 weeks. The total effective rate of treatment of stroke, incidence of adverse reactions, neurological deficit scores, platelet aggregation, erythrocyte aggregation index and lysosomal granular membrane glycoprotein in the two groups were compared. Results The total effective rate of stroke in observation group was 94.87% higher than 76.92% in control group (P <0.05). The incidence of adverse reactions in observation group was the same as that in control group, with no significant difference (P> 0.05). There were no significant differences in neurological deficit score, platelet aggregation, erythrocyte aggregation index and lysosomal granular membrane glycoprotein between the two groups before treatment (P> 0.05); after treatment, the neurological deficit score, platelet aggregation, erythrocyte Aggregation index, lysosomal granular membrane glycoprotein were lower than the control group (P <0.05). Conclusions Fibrinolytic enzyme can improve the function of disability in patients with stroke effectively. It can effectively improve the hemorrheological indexes, alleviate the symptoms of neurological deficits, improve the prognosis of patients, and have no serious adverse reactions after the drug treatment, so it has good safety Sex.